Publications by authors named "Jennifer Pizzano"

Claim this Profile
C
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models".
Michael Berlin, Jennifer Cantley, Mark Bookbinder, Elizabeth Bortolon, Fabio Broccatelli, Jennifer Pizzano

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.
Lawrence B Snyder, Taavi K Neklesa, Ryan R Willard, Deborah A Gordon, Jennifer Pizzano

Mol Cancer Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
Sheryl M Gough, John J Flanagan, Jessica Teh, Monica Andreoli, Emma Rousseau, Jennifer Pizzano

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs.
Donglu Zhang, Bin Ma, Peter S Dragovich, Li Ma, Shu Chen, Jennifer Pizzano

Commun Med (Lond)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROTACs Targeting BRM (SMARCA2) Afford Selective Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
Michael Berlin, Jennifer Cantley, Mark Bookbinder, Elizabeth Bortolon, Fabio Broccatelli, Jennifer Pizzano

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs.
Ponien Kou, Elizabeth S Levy, An D Nguyen, Donglu Zhang, Shu Chen, Jennifer Pizzano

Pharmaceutics· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, Tom Januario, Brian D Hamman, Jennifer Pizzano

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of regional absorption and gastrointestinal motility on variability in oral absorption of a model drug.
Ajit S Narang, Anand Balakrishnan, John Morrison, Jinjiang Li, Jennifer Wang, Jennifer Pizzano

Eur J Pharm Biopharm· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Sean Kim, Joseph E Dinchuk, Monique N Anthony, Tami Orcutt, Mary E Zoeckler, Jennifer Pizzano

Drug Metab Dispos· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential.
Sean Kim, Devin Pray, Ming Zheng, Daniel G Morgan, Jennifer G Pizzano

Drug Metab Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis